Pharma & biotech news
Aytu: $57.6M revenue, $0 R&D (0.0% of revenue), year to Jun 2026
Aytu filed a 10-K with the SEC on 22 Sep 2026 covering the period ending 30 Jun 2026: revenue $57.6 million (57,570,000 USD) and R&D spend $0 (0 USD), which is 0.0% of that revenue; net income $-14,252,000 (-14,252,000 USD).